BTAI
BTAI
NASDAQ · Biotechnology

Bioxcel Therapeutics Inc

$1.15
-0.06 (-4.96%)
As of May 16, 2:23 AM ET ·
Financial Highlights (FY 2026)
Revenue
1.44M
Net Income
-156,363,504
Gross Margin
74.4%
Profit Margin
-10,887.4%
Rev Growth
+19.1%
D/E Ratio
1.21
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 74.4% 74.4% 67.3% 67.3%
Operating Margin -7,860.0% -7,074.0% -12.1% -10.8%
Profit Margin -10,887.4% -10,343.0% -10.7% -10.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.44M 1.21M 5.52M 6.67M
Gross Profit 1.07M 898.0K 3.71M 4.49M
Operating Income -112,908,940 -85,321,617 -670,275 -720,471
Net Income -156,363,504 -118,158,819 -589,967 -686,380
Gross Margin 74.4% 74.4% 67.3% 67.3%
Operating Margin -7,860.0% -7,074.0% -12.1% -10.8%
Profit Margin -10,887.4% -10,343.0% -10.7% -10.3%
Rev Growth +19.1% +19.1% -1.7% -4.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 8.60M 8.60M 5.54M 6.52M
Total Equity 7.10M 7.10M 24.64M 23.32M
D/E Ratio 1.21 1.21 0.23 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -120,082,146 -95,783,407 -924,468 -1,114,371
Free Cash Flow -774,673 -818,976